Visiox Pharma LLC, a US-based, privately funded biopharmaceutical company, announced on Wednesday that it has appointed Vicente Anido Jr., Ph.D. as its new strategic advisor.
Anido has previously served as chief executive officer at Aerie Pharmaceuticals and at ISTA Pharmaceuticals.
Anido said: "This is an exciting time in eye care to establish a new company that is following in the footsteps of a proven commercial platform. I am eager to help bring two novel drugs to the largest eye care markets inside a year while evaluating additional late-stage products to expand the Visiox pipeline."
BioCare climbs 1,145 places on Inc. 5000 list
DuPont recognised with R&D 100 Award for innovation in healthcare
Synaptiq Therapeutics launches and acquires clinical-stage SYN-001 programme
WuXi AppTec named to FTSE4Good Index Series for fourth consecutive year
EDX Medical to provide molecular profiling services to Astron Health
Futura Medical appoints Market Performance Group as new US distribution partner for Eroxon
MaaT Pharma to seek review after CHMP negative opinion on MaaT013 application
Sensei Biotherapeutics changes name to Faeth Therapeutics
Datavault AI and Wellgistics Health plan DelivMeds AI healthcare venture